Nasus Pharma Ltd. will present data on NS002, its intranasal epinephrine powder formulation, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2. The poster presentation will compare the effectiveness of nasal powder versus liquid spray for anaphylaxis treatment, highlighting the potential advantages of the powder technology. NS002 aims to provide rapid epinephrine delivery in emergency situations. The stable nature of the FMXIN002 Epinephrine Intranasal Powder Spray will also be discussed at the meeting. Nasus Pharma is focused on developing needle-free intranasal products for acute medical conditions, with NS002 offering a unique delivery option for anaphylaxis treatment.

Read more at GlobeNewswire: Nasus Pharma to Present Data Highlighting Superior Nasal